DRNA - ディサ―ナ・ファ―マシュ―ティカルズ （Dicerna Pharmaceuticals Inc.） ディサ―ナ・ファ―マシュ―ティカルズDRNAのチャート
DRNAの企業情報
| symbol | DRNA |
|---|---|
| 会社名 | Dicerna Pharmaceuticals Inc （ディサ―ナ・ファ―マシュ―ティカルズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 Dicerna Pharmaceuticals Inc. is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined. The Company uses its RNAi technology platform to build a pipeline in these therapeutic areas. The Company develops dacryocystorhinostomy (DCR)-Primary Hyperoxaluria Type 1 (PH1) for the treatment of PH1 by targeting the gene encoding the liver enzyme glycolate oxidase. The Company uses its dicer substrate RNA (DsiRNA)-EX Conjugate technology to develop a subcutaneously injected treatment for PH1. The Company develops DCR-MYC for the treatment of MYC-related cancers including hepatocellular carcinoma (HCC) and pancreatic neuroendocrine tumors (PNET). ディサ―ナ・ファ―マシュ―ティカルズは、米国のバイオ医薬品会社。肝臓の遺伝性疾患などの癌のためのRNA干渉技術プラットフォ―ムを使用した治療法の発見と開発に焦点を当てる。同社は、｢DCR-PH1｣と｢DCR-M1711｣製品を開発している。また癌遺伝子キルステンラット肉腫ウイルス癌遺伝子ホモログを対象に開発する。 |
| 本社所在地 | 87 Cambridgepark Drive Cambridge MA 02140 USA |
| 代表者氏名 | David M. Madden David M. Madden |
| 代表者役職名 | Independent Chairman of the Board |
| 電話番号 | +1 617-621-8097 |
| 設立年月日 | 38991 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2014年 |
| 従業員数 | 44人 |
| url | www.dicerna.com |
| nasdaq_url | https://www.nasdaq.com/symbol/drna |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -59.59300 |
| 終値（lastsale） | 14.19 |
| 時価総額（marketcap） | 877039981.95 |
| 時価総額 | 時価総額（百万ドル） 837.03670 |
| 売上高 | 売上高（百万ドル） 4.98200 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 763.63970 |
| 当期純利益 | 当期純利益（百万ドル） -93.17100 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Dicerna Pharmaceuticals Inc revenues increased from $0K to $3.1M. Net loss applicable to common stockholders increased 34% to $51.2M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Litigation expense increase from $2.2M to $22.2M (expense). |
DRNAのテクニカル分析
DRNAのニュース
B.Riley Financial Stick to Their Buy Rating for Dicerna Pharma By Investing.com 2021/01/11 07:45:05 Investing.com
B.Riley Financial Stick to Their Buy Rating for Dicerna Pharma
H.C. Wainwright Stick to Their Buy Rating for Dicerna Pharma 2021/01/04 16:55:00 Investing.com
H.C. Wainwright Stick to Their Buy Rating for Dicerna Pharma
Global Antisense and RNAi Therapeutics Market 2020-2027:, Size, Opportunities, Trends, Regional Overview,Covering Impact of COVID-19, SWOT Analysis By Alnylam Pharmaceuticals, Inc, Dicerna Pharmaceuticals, Tekmira Pharmaceuticals 2020/12/31 10:32:29 OpenPR
The forecast period 2020-2027 is going to be great for the Antisense and RNAi Therapeutics market which will be the face changer for Pharmaceutical industry. The users are increasing day by day hence increasing the sales, import, export, revenue and
Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) Insider Sells $343,770.00 in Stock 2020/10/23 04:46:41 Dispatch Tribunal
Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) insider Bob D. Brown sold 16,370 shares of the business’s stock in a transaction dated Friday, October 16th. The shares were sold at an average price of $21.00, for a total value of $343,770.00. Following the completion of the transaction, the insider now owns 42,887 shares in the company, valued at […]
Insider Selling: Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) COO Sells $176,144.00 in Stock 2020/10/22 06:06:42 Stock Observer
Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) COO James B. Weissman sold 8,720 shares of the firm’s stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $20.20, for a total transaction of $176,144.00. Following the completion of the sale, the chief operating officer now owns 30,580 shares of the company’s […]
Global Antisense and RNAi Therapeutics Market Shows Strong Growth with Leading Players are Astellas Pharma Inc, Quark, Alnylam Pharmaceuticals, Inc, Dicerna Pharmaceuticals, Tekmira Pharmaceuticals, Benitec Biopharma 2020/10/01 14:41:00 OpenPR
DBMR has added a new report titled Antisense and RNAi therapeutics market with analysis provides the insights which bring marketplace clearly into the focus and thus help organizations make better decisions. The data and the information regarding the industry are
Global RNA Interference Market To See Astonishing Growth By 2027|Covid 19 Impact Analysis By Arcturus Therapeutics, Inc., Arrowhead Pharmaceuticals, Inc., Dicerna Pharmaceuticals, Inc., Ionis Pharmaceuticals 2020/09/30 17:03:08 OpenPR
This research report acknowledges the presentation segments of the global market. The market was classified in terms of presentation in the next piece. The report highlights substantial market growth trends and dynamics, including limitations, drivers and opportunities. A number of
Global Antisense and RNAi Therapeutics Market Sees a Faster Rebound in the Era of COVID-19 | Industry Size, Share, Growth Factors, Development Strategy, Top Leaders-Astellas Pharma Inc, Quark, Alnylam Pharmaceuticals, Inc, Dicerna Pharmaceuticals, Tekmira 2020/09/30 08:44:11 OpenPR
DBMR has added a new report titled Global Antisense and RNAi Therapeutics Market with analysis provides the insights which bring marketplace clearly into the focus and thus help organizations make better decisions. The data and the information regarding the industry are taken
Dicerna guides Roche-partnered hepatitis B drug past early test 2020/08/06 12:09:08 FierceBiotech
Dicerna Pharmaceuticals has shared interim phase 1 data on its Roche-partnered hepatitis B drug RG6346. The trial linked RG6346 to reductions in hepatitis B surface antigen (HBsAg) that suggest the RNAi therapy can hold its own against rival candidates in development at Johnson & Johnson and Vir Biotechnology.
Dicerna Pharmaceuticals (DRNA) Reports Q1 Loss, Misses Revenue Estimates 2020/05/07 22:45:14 Zacks Investment Research
Dicerna Pharmaceuticals (DRNA) delivered earnings and revenue surprises of -210.71% and -42.92%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Dicerna guides Roche-partnered hepatitis B drug past early test 2020/08/06 12:09:08 FierceBiotech
Dicerna Pharmaceuticals has shared interim phase 1 data on its Roche-partnered hepatitis B drug RG6346. The trial linked RG6346 to reductions in hepatitis B surface antigen (HBsAg) that suggest the RNAi therapy can hold its own against rival candidates in development at Johnson & Johnson and Vir Biotechnology.
Dicerna Pharmaceuticals (DRNA) Reports Q1 Loss, Misses Revenue Estimates 2020/05/07 22:45:14 Zacks Investment Research
Dicerna Pharmaceuticals (DRNA) delivered earnings and revenue surprises of -210.71% and -42.92%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Alnylam and Dicerna Form RNAi Therapeutics Collaboration on Alpha-1 Antitrypsin Deficiency-Associated Liver Disease and Complete Cross-License Agreement for Primary Hyperoxaluria Programs 2020/04/06 11:00:00 Business Wire
CAMBRIDGE, Mass. & LEXINGTON, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), and Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), both leaders in the field of ribonucleic acid interference (RNAi) therapeutics, announced today the formation of a development and commercialization collaboration on investigational RNAi therapeutics for the treatment of alpha-1 antitrypsin (A1AT) deficiency-associated liver disease (alpha-1 liver disease). In addition, the companies have complete
Dicerna's (DRNA) A1AT Candidate Gets Orphan Drug Tag in EU 2019/12/18 10:03:00 Zacks Investment Research
The European Commission confers an orphan drug status on Dicerna's (DRNA) RNAi therapeutic DCR-A1AT for the treatment of congenital alpha-1 antitrypsin (A1AT) deficiency.
The Daily Biotech Pulse: Aurinia Rips Higher On Positive Readout, Sesen Bio On Track For Vicinium BLA Submission 2019/12/05 12:14:16 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Dec. 4) Allakos Inc (NASDAQ: ALLK )(announced exploration of strategic options, including a potential sale) Allergan plc (NYSE: AGN ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Applied Therapeutics Inc (NASDAQ: APLT ) Audentes Therapeutics Inc (NASDAQ: BOLD ) Axsome Therapeutics Inc (NASDAQ: AXSM ) Bausch Health Companies Inc (NYSE: BHC ) Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO ) Cue Biopharma Inc (NASDAQ: CUE ) Deciphera Pharmaceuticals Inc (NASDAQ: DCPH ) DexCom, Inc. (NASDAQ: DXCM ) Dicerna Pharmaceuticals Inc (NASDAQ: DRNA ) Flexion Therapeutics Inc (NASDAQ: FLXN ) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) Global Blood Therapeutics Inc (NASDAQ: GBT ) Gossamer Bio Inc (NASDAQ: GOSS ) Incyte Corporation (NASDAQ: INCY ) Inspire Medical Systems Inc (NYSE: INSP ) IVERIC bio Inc (NASDAQ: ISEE ) Jounce Therapeutics Inc (NASDAQ: JNCE ) Kodiak Sciences Inc (NASDAQ: KOD ) Krystal Biotech Inc (NASDAQ: KRYS ) Merck & Co.